Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,745.5 11/10/16
52 week low1,444.0 19/09/17
52 week change -162.5 (-10.06%)
4 week volume162,014,593 24/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

FTSE gains supported by BP, Shell and sterling retreat

Oil giants BP (BP.) and Royal Dutch Shell (RDSB) boosted the FTSE 100 thanks to stable oil prices. Brent crude oil advanced...

Trelegy Ellipta: FDA approval in COPD received

RNS Number: 0979R GlaxoSmithKline PLC 18 September 2017 Issued: 18 September 2017, London UK - LSE Announcement Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the...

Investors to receive £8.2 billion dividend windfall

UK companies are among the most generous around, and shareholders are about to be rewarded for their loyalty, writes L...

Trelegy Ellipta: positive opinion from CHMP Europe

RNS Number: 8326Q GlaxoSmithKline PLC 15 September 2017 Issued: 15 September 2017, London UK - LSE Announcement Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced tha...

FDA committee recommends GSK shingles vaccine

GlaxoSmithKline has announced that the US Food and Drug Administration's vaccines and related biological products adv...

Unanimous FDA approval for Shingrix in over 50s

RNS Number: 7262Q GlaxoSmithKline PLC 14 September 2017 Issued: 13 September 2017, London UK FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the Vaccines and Related Biological Products Advisory C...

Broker Forecast - JP Morgan Cazenove issues a broker note on GlaxoSmithKline PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price...

Director/PDMR Shareholding

RNS Number: 5501Q GlaxoSmithKline PLC 12 September 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market partic...

Fundamental DataMore

P/E ratio77.312
EPS18.8
Dividend yield5.504 %

Latest discussion posts More

  • NEW ARTICLE: Investors to receive A#8.2 billion dividend windfall

    "Over the next four weeks, some of the UK's biggest companies will send dividend cheques to shareholders totalling a staggering A#8.2 billion. And the good news is that almost ...
    18-Sep-2017
    II Editor
  • Re: Crop haired thug ... GSK or LLOY ???

    Bother!.... The plotting link didn't work properly. Need to reset the start date to 29th May to see the correct time frame. Grill
    18-Sep-2017
    Grill Bimsie
  • Re: Crop haired thug ... GSK or LLOY ???

    Having followed the daily updates from late May for 30+ trading days I was curious, so plotted this for my own interest. Pretty much neck and neck up to this point, after an ...
    18-Sep-2017
    Grill Bimsie

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
BP34%
VODAFONE GRP.34%
NATIONAL GRID32%
LLOYDS GRP.32%
RDS 'B'31%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK